|
Press Release Archives
2009 2008 2007 2006 2005 
Search ReleasesNovember Wednesday, Nov 18, 2009 Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia Monday, Nov 16, 2009 Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer October Saturday, Oct 17, 2009 Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission Saturday, Oct 17, 2009 Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis Sunday, Oct 04, 2009 Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion September Wednesday, Sep 16, 2009 Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance August Monday, Aug 17, 2009 Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer Sunday, Aug 02, 2009 FDA Approves Avastin for the Most Common Type of Kidney Cancer July Thursday, Jul 30, 2009 Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion Tuesday, Jul 28, 2009 Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology Sunday, Jul 19, 2009 Xeloda®-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer Sunday, Jul 12, 2009 New Data from Phase III Saturn Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer Thursday, Jul 02, 2009 Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion May Saturday, May 30, 2009 Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy Saturday, May 30, 2009 Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer Friday, May 29, 2009 Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer Tuesday, May 19, 2009 Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia Thursday, May 14, 2009 Genentech to Present Advances With Targeted Cancer Medicines at ASCO Tuesday, May 05, 2009 FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy April Tuesday, Apr 21, 2009 Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint Wednesday, Apr 08, 2009 Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market March Tuesday, Mar 31, 2009 FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma) Thursday, Mar 26, 2009 Roche Completes Acquisition of Genentech Wednesday, Mar 18, 2009 OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Thursday, Mar 12, 2009 Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation Wednesday, Mar 11, 2009 Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint Friday, Mar 06, 2009 Genentech Urges Stockholders to Take No Action With Respect to Revised Offer From Roche February Tuesday, Feb 24, 2009 Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding Monday, Feb 23, 2009 Genentech Announces March 2, 2009 Webcast of Investment Community Meeting Monday, Feb 23, 2009 Genentech Special Committee Rejects Roche's $86.50 Offer as Inadequate Thursday, Feb 19, 2009 National Coalition for Cancer Survivorship, UCLA, Wellpoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer Monday, Feb 09, 2009 Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer from Roche Monday, Feb 02, 2009 Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer January Friday, Jan 30, 2009 Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer Wednesday, Jan 21, 2009 Genentech Announces Vice President Appointment in Research Thursday, Jan 15, 2009 Genentech Announces Full Year And Fourth Quarter 2008 Results
 |
